Overview
Dr. Brian Mac Grory, MB BCh BAO, MHSc, MRCP, FAHA, FANA is an Associate Professor of Neurology, Ophthalmology & Biomedical Engineering at the Duke University School of Medicine and a Staff Neurologist at Duke University Medical Center. He received his medical degree from University College Dublin in Dublin, Ireland in 2011. After an internship at St. Vincent's University Hospital, Dublin, he completed a neurology residency and vascular neurology fellowship at the Yale School of Medicine/Yale-New Haven Hospital in New Haven, Connecticut. Upon completion of his training, he served for 3 years on the faculty of Brown University/Rhode Island Hospital before being recruited to Duke University in 2020.
His clinical practice encompasses both vascular and general neurology in the emergency, inpatient, outpatient, and telemedicine settings. He has a particular clinical interest in central retinal artery occlusion (CRAO or "eye stroke") and has developed a center of excellence for the treatment of this condition at Duke. He led the development of the first ever American Heart Association (AHA) scientific consensus statement on the management of CRAO which was endorsed by six professional medical societies in the United States representing neurology, neurosurgery, cardiology, ophthalmology, neuro-ophthalmology, and optometry.
Dr. Mac Grory has published over 150 peer-reviewed scientific articles appearing in JAMA, British Medical Journal, Circulation, Stroke, Annals of Neurology, JAMA Neurology, and Neurology. At the Duke Clinical Research Institute, he directs the Observational Research Building Interdisciplinary Therapeutic Advances (ORBIT) Interdisciplinary Hub. His research on retinal vascular disease is funded by the National Institutes of Health (K23HL161426, UG3NS138219, & R03HL178686), the AHA (23MRFSCD1077188 & 25GLP1450119), and the Duke University Office of the Provost. Additionally, he serves as Clinical Lead for the Get With The Guidelines-Stroke Data Analytic Program at the Duke Clinical Research Institute (DCRI) and Associate Program Director for the vascular neurology fellowship program at Duke. His research has been recognized with the Stroke Progress and Innovation Award, Stroke Care in Emergency Medicine Award, and Early Career Investigator Award from the AHA/American Stroke Association and the Young Physician-Scientist Award from the American Society for Clinical Investigation. He is a member of the AHA's Stroke Systems of Care Advisory Group, the Stroke Emergency Neurovascular Care Committee, and the Royal College of Physicians of the United Kingdom (MRCP(UK)).
Current Appointments & Affiliations
Recent Publications
Stroke Risk After Bioprosthetic Aortic Valve Replacement in Aortic Stenosis: Systematic Review and Meta-Analysis.
Journal Article Stroke · June 2026 BACKGROUND: Stroke is a possible complication after bioprosthetic aortic valve replacement (AVR) for severe aortic stenosis (AS), impacting morbidity and mortality. Accurate estimates of the proportion of individuals who experience stroke within and beyond ... Full text Link to item CiteRural-Urban Disparity in Postacute Care and 1-Year Outcomes After Ischemic Stroke.
Journal Article Stroke · May 28, 2026 BACKGROUND: Rural residents have been experiencing higher stroke mortality than urban residents, and the gap has widened. Disparity in postacute care after stroke may increase the rural-urban gaps of mortality and disability. We aimed to examine whether ru ... Full text Link to item CitePossible Diagnostic Error in Cervical Artery Dissection: Analysis of STOP-CAD Study.
Journal Article J Am Heart Assoc · May 19, 2026 BACKGROUND: Cervical artery dissection (CeAD) is a common cause of stroke in young adults but is frequently misdiagnosed due to its nonspecific symptoms. This study examines factors associated with possible diagnostic error in CeAD and evaluates its impact ... Full text Link to item CiteRecent Grants
Induced Suppression of Platelet Activity in Aneurysmal SAH Management-2 (iSPASM-2)
Clinical TrialCo-Principal Investigator · Awarded by National Institutes of Health · 2025 - 2030A multicenter, international, randomized, placebo controlled, double-blind, parallel group and event driven Phase 3 study of the oral FXIa inhibitor asundexian (BAY 2433334) for the prevention of isch
Clinical TrialPrincipal Investigator · Awarded by Bayer Healthcare Pharmaceuticals Inc · 2023 - 2027Cardioembolism as a Mechanism of Central Retinal Artery Occlusion
ResearchPrincipal Investigator · Awarded by National Heart, Lung, and Blood Institute · 2022 - 2027View All Grants